McMaster School of Interdisciplinary Science, Faculty of Science, McMaster University, Hamilton, Ontario, Canada.
Department of Anesthesiology, Michael DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Eur J Pain. 2019 Aug;23(7):1234-1250. doi: 10.1002/ejp.1393. Epub 2019 Apr 10.
N-methyl-D-aspartate (NMDA) receptors are involved in pain signalling and neuroplasticity. Memantine has been shown to have analgesic properties in pre-clinical and small clinical studies. We conducted a systematic review and meta-analysis to assess the efficacy of memantine to prevent or reduce chronic pain.
MEDLINE, EMBASE and CENTRAL databases were searched for comparative trials using memantine, either against placebo or active medications, for chronic pain in adults. Pain relief was considered our primary outcome. Meta-analyses were conducted if outcomes were reported in two or more studies. Outcomes were reported as mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI). Quality was assessed using the GRADE approach.
Among 454 citations, 15 studies were included with populations predominantly consisting of neuropathic conditions and fibromyalgia. Overall, we observed unclear reporting of randomization and allocation methods, apart from potential for publication bias. Among the 11 studies looking at chronic pain treatment, the difference in end pain score with memantine was not significant: MD = -0.58 units (95% CI -1.31, 0.14); I = 82% (low quality). In two surgical studies using memantine for pain prevention, memantine decreased pain intensity: MD = -1.02 units (95% CI -1.38, -0.66); I = 0%. Dizziness was significantly more common with memantine: RR = 4.90 (95% CI 1.26, 18.99); I = 52% (moderate quality).
The current evidence regarding the use of memantine for chronic pain is limited and uncertain. Despite its potential, pain relief achieved in clinical studies is small and is associated with an increase in dizziness.
Despite a sound rationale, the benefit of using memantine for chronic pain is unclear. Our systematic review and meta-analysis show that memantine may have the potential to decrease pain. However, it can also increase common adverse effects. Considering the small number of studies with potential for bias and inconclusive evidence, there was low to very low certainty. Hence, no clear recommendations can be made about its routine clinical use until larger and more definitive studies are conducted.
N-甲基-D-天冬氨酸(NMDA)受体参与疼痛信号传递和神经可塑性。在临床前和小型临床研究中,已证明美金刚具有镇痛作用。我们进行了系统评价和荟萃分析,以评估美金刚预防或减轻慢性疼痛的疗效。
在 MEDLINE、EMBASE 和 CENTRAL 数据库中搜索了使用美金刚的对照试验,美金刚用于治疗成人慢性疼痛,与安慰剂或活性药物进行比较。缓解疼痛被认为是我们的主要结局。如果两项或多项研究报告了结果,则进行荟萃分析。结果以均值差(MD)或风险比(RR)和 95%置信区间(CI)表示。使用 GRADE 方法评估质量。
在 454 条引文中有 15 项研究入选,这些研究的人群主要由神经病变和纤维肌痛组成。总体而言,除了可能存在发表偏倚外,我们还发现随机和分配方法的报告不清楚。在 11 项研究中,使用美金刚治疗慢性疼痛,美金刚对终末疼痛评分的影响不显著:MD=-0.58 单位(95%CI-1.31,0.14);I=82%(低质量)。在两项使用美金刚预防疼痛的手术研究中,美金刚降低了疼痛强度:MD=-1.02 单位(95%CI-1.38,-0.66);I=0%。美金刚引起头晕的发生率显著增加:RR=4.90(95%CI 1.26,18.99);I=52%(中等质量)。
目前关于美金刚治疗慢性疼痛的证据有限且不确定。尽管有其潜在作用,但临床研究中获得的疼痛缓解程度较小,且与头晕发生率增加有关。
尽管有合理的理论依据,但美金刚治疗慢性疼痛的益处尚不清楚。我们的系统评价和荟萃分析表明,美金刚可能有潜力减轻疼痛。然而,它也会增加常见的不良反应。考虑到存在偏倚和证据不确定的研究数量较少,证据质量为低到极低。因此,在进行更大和更明确的研究之前,不能对其常规临床应用提出明确的建议。